Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.

MLA

Coutts, Shelagh B., et al. “Tenecteplase versus Standard of Care for Minor Ischaemic Stroke with Proven Occlusion (TEMPO-2): A Randomised, Open Label, Phase 3 Superiority Trial.” Lancet (London, England), vol. 403, no. 10444, June 2024, pp. 2597–605. EBSCOhost, https://doi.org/10.1016/S0140-6736(24)00921-8.

APA

Coutts, S. B., Ankolekar, S., Appireddy, R., Arenillas, J. F., Assis, Z., Bailey, P., Barber, P. A., Bazan, R., Buck, B. H., Butcher, K. S., Camden, M.-C., Campbell, B. C. V., Casaubon, L. K., Catanese, L., Chatterjee, K., Choi, P. M. C., Clarke, B., Dowlatshahi, D., Ferrari, J., … Hill, M. D. (2024). Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial. Lancet (London, England), 403(10444), 2597–2605. https://doi.org/10.1016/S0140-6736(24)00921-8

Chicago

Coutts, Shelagh B, Sandeep Ankolekar, Ramana Appireddy, Juan F Arenillas, Zarina Assis, Peter Bailey, Philip A Barber, et al. 2024. “Tenecteplase versus Standard of Care for Minor Ischaemic Stroke with Proven Occlusion (TEMPO-2): A Randomised, Open Label, Phase 3 Superiority Trial.” Lancet (London, England) 403 (10444): 2597–2605. doi:10.1016/S0140-6736(24)00921-8.